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Abstract: Crohn’s disease and ulcerative colitis are inﬂ  ammatory bowel diseases (IBD) quite common in the United States 
and other Western countries. Patients suffering IBD are at greater risk of developing colorectal adenocarcinoma than the 
general population. Both, the adenoma-carcinoma and the inﬂ  ammation-carcinogenesis processes are characterized by active 
angiogenesis. Recent studies also have shown that anti-angiogenesis might be a novel therapeutic approach for IBD. Throm-
bospondin 1 (TSP1) is an extracellular protein well known for its anti-angiogenic properties. TSP1 also has key functions 
in inﬂ  ammation, which is assumed to be the primary cause for carcinogenesis in IBD. This review is focused on the role of 
TSP1 in colorectal carcinogenesis. The therapeutic effects of TSP derived-peptides on inhibiting the inﬂ  ammation-
carcinogenesis progression are also discussed.
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The role of inﬂ  ammation in carcinogenesis has been broadly corroborated.(1) Granulocytes and 
monocytes produce growth factors and cytokines that stimulate tumor growth and induce changes in 
the stroma of tissues. These growth factors and cytokines also increase angiogenesis promoting tumor 
expansion and metastasis. Inﬂ  ammatory cells produce reactive oxygen species that induce DNA 
damage.(2,3) DNA damage increases proliferation and induces cell genetic instability. All of these 
mechanisms will increase the chance of mutations and consequent malignancy.
There are many examples in which cancer is induced and promoted by inﬂ  ammation. Colorectal 
carcinomas are among the best demonstrations for the crucial role of inﬂ  ammation in cancer.(4) Chronic 
inﬂ  ammation is a signiﬁ  cant inductor of colorectal adenocarcinoma. The sequence hyperplasia-adenoma-
carcinoma for sporadic human colon cancer has been well studied.(5) However, the etiology and 
mechanisms involved in the transition from chronic inﬂ  ammation-ulceration to dysplasia-carcinoma 
are not so well known.
Inﬂ  ammatory bowel disease (IBD) such as Crohn’s disease and ulcerative colitis (UC) affect children 
and adults and they are recognized as premalignant disorders.(6,7) Sustained nitrosative/oxidative stress 
and DNA damage generated during chronic inﬂ  ammation characterize IBD-related carcinogenesis.
UC-carcinogenesis could be a consequence of two main pathways: inflammation and 
hyperproliferation.(2) Previous experiments have shown that high levels of inﬂ  ammation might trigger 
the initiation of dysplasia and the increased proliferation in the reactive epithelium could augment the 
chances for mutations.
The role of inﬂ  ammation in colorectal carcinoma is demonstrated by the fact that non-steroidal 
anti-inﬂ  ammatory drugs cause a dramatic involution of adenomas, the precursors of carcinomas.(8)
Angiogenesis is a landmark of cancer development and metastasis.(9) In addition there is a direct 
link between angiogenesis and inﬂ  ammation.(10,11) Radical changes occur in the endothelium upon 
acute and chronic inﬂ  ammation. Endothelial activation, dilation, increased permeability and leukocytic 
diapedesis are observed initially. Leukocytes and endothelial cells secrete high levels of interleukins, 
chemokines and growth factors enhancing the immune response and promoting angiogenesis.(10,11) 
The hyperproliferation and angiogenesis initiated by these factors as well as the DNA damage induced 
by leukocytic oxygen species all provide a foundation for carcinogenesis.(1,2)172
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The endothelium also secretes molecules that 
inhibit the immune response. As an example, fac-
tors involved in the protein C pathway are activated 
during inﬂ  ammation and endothelial activation as 
well as leukocyte adhesion are both diminished.(12) 
These and other anti-inflammatory molecules 
might play a signiﬁ  cant role in environments such 
as intestine and lung in which immune tolerance 
is critical.
Multiple evidence points to thrombospondin 1 
(TSP1) as an inhibitor of angiogenesis and inﬂ  am-
mation in vitro and in vivo.(13,14) In this review, 
the roles of TSP1 in colorectal carcinogenesis and 
inﬂ  ammation are analyzed as well as the therapeu-
tic effects of a TSP-derived peptide in IBD-related 
carcinogenesis.
These studies strongly suggest an important role 
of TSP1 in the mechanisms developing IBD and 
cancer. The use of TSP1 derived peptides could 
represent an innovative strategy to attenuate 
chronic inﬂ  ammation and delay colorectal carci-
nogenesis.
The Thrombospondins
The thrombospondins (TSP) include ﬁ  ve calcium-
binding extracellular glycoproteins.(13,14) TSP1 
was the ﬁ  rst to be identiﬁ  ed and was detected in 
the α-granules released after platelet activation. 
TSP1 is also a component of the extracellular 
matrix.(16) The TSP family displays a series of 
epidermal growth factor-type repeats(TSR) called 
TSP type 2 repeats, and seven calcium binding 
repeats called TSP type 3 repeats.(16,17) Both, 
TSP1 and TSP2 have in addition three distinct 
repeats called TSP type 1 repeats.(15) These 
repeats (TSP structural repeats or TSR) are impor-
tant in the functions of TSP1 and TSP2.(13–17)
The functions of TSP1 have been extensively 
studied in many laboratories. TSP1 is involved in 
the formation and resolution of a ﬁ  brin clot and binds 
to many proteins and proteases.(16) TSP1 interacts 
with heparan sulfates, proteoglycans, integrins, 
fibrinogen and fibronectin.(18) It also binds to 
components of the ﬁ  brinolytic system (plasminogen, 
urokinase and its inhibitor PAI-1)(19,20) and to 
cathepsin G and elastase.(21)
Numerous cell assays attribute functions to 
TSP1 in cell proliferation, apoptosis, angiogen-
esis inhibition, cell attachment and motility.(22) 
Most of these functions are shared with 
TSP2,(13–17) especially the inhibition of (EC) 
proliferation and angiogenesis. However, a motif 
KRFK between the ﬁ  rst and second TSR binds 
and activates latent transforming growth factor 
beta 1 (TGFβ1); this site is not preserved in TSP2. 
Therefore TSP2 is unable to activate TGFβ1.(23,24) 
Through its binding to TGFβ1, TSP1 modulates 
cytokine response and secretion of other growth 
factors.(25)
Of great importance is the interaction of TSP1 
with the scavenger receptor CD36. CD36 is 
expressed in endothelium (small vessels) and a 
variety of epithelial and stromal cells.(26) Some 
of the antiangiogenic functions of TSP1 are 
directly mediated by the binding of TSP1 with 
CD36.(27) TSP1 also has important functions in 
inﬂ  ammation that are dependent of its binding 
with CD36.(28)
TSP1 is an inhibitor of EC proliferation.(29,30) 
However, its inhibitory effects on epithelial 
proliferation seem to be cell-dependent. TSP1 may 
modulate cell proliferation via TGFβ1or by inhibiting 
angiogenesis.(31) The TGFβ1family has direct 
inhibitory properties on epithelial proliferation. After 
its activation by integrins, proteases or by TSP1, 
TGFβ1binds to its receptors: TGFβRI and TGFβRII. 
This process activates intracellular transcription fac-
tors called Smad 2 and Smad 3 that subsequently 
combine with Smad 4. This complex moves to the 
nucleus and activates regulatory genes. Genes 
involved in the cell cycle process such as the proto-
oncogene c-myc, cyclins and p21 are regulated by 
this mechanism. Interestingly, mice deﬁ  cient in Smad 
2 develop more dysplasia and carcinomas after 
induction of chronic colitis.(32)
More recently, TSP1 has been reported to block 
the pro-angiogenic effects of nitric oxide (NO) in 
endothelial and vascular smooth muscle cells.(33) 
Low level of NO are anti-inﬂ  ammatory, but in 
inﬂ  amed tissues the levels of NO increase and 
blood ﬂ  ow, vascular permeability and angiogen-
esis are enhanced.(11) By interacting with their 
receptors CD36 and CD47, TSP1 prevents the pro-
angiogenic effects of NO and makes EC more 
susceptible to its inhibition.(33)
The anti-angiogenic effects of TSP1 may also 
be CD36 independent, it suppresses the cell cycle, 
increasing p21 and unphosphorylated retinoblas-
toma (Rb) in EC.(34) Many receptors interact 
with speciﬁ  c binding sites of TSP1. The sites 
with the anti-angiogenic functions have been 
recognized in the procollagen domain and type 1 
repeats (TSR) sequences. TSR of TSP1 block 173
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vascular endothelial growth factor (VEGF)-
induced migration of human umbilical vein endo-
thelial cells (HUVEC) which lack CD36 and this 
inhibition is mediated by beta1 integrins.(35) TSP1 
also interacts with other receptors involved in 
angiogenesis and inﬂ  ammation such as integrin 
αvβ3 integrins,(36) proteoglycans and the integrin-
associated protein CD47.(37) A component of the 
β3 integrin complex, CD47 is expressed in T cells 
and polymorphonuclear cells and it has a crucial 
role in T cell stimulation.(38,39)
By interacting with CD47, TSP1 might contrib-
ute to the quiescence state and self-tolerance in 
tissues such as intestine and lung. Upon binding 
with CD47, TSP1 promotes the activation of thy-
mus-derived CD4
+ CD25
+ T regulatory cells 
(Tregs). These cells help to maintain self-tolerance 
and induce a suppressive phenotype.(40) Also, the 
disruption of the CD47/TSP1 pathway diminishes 
T cell apoptosis and delays leukocytic clearance 
in animal models.(41)
TSP1 in Intestinal Inﬂ  ammation
TSP1 increases neutrophil adhesion and migration. 
Also, TSP1 supports monocyte chemotaxis, hap-
totaxis, and diapedesis.(38,39) TSP1 might have 
a role in the clearance of inﬂ  ammatory cells.(41) 
Inﬂ  ammation and chronic conditions have been 
reported to show high expression of TSP1.(42)
The TSP1 null adult mice(43) have showed 
leukocytosis and abnormal inﬂ  ammatory cell inﬁ  l-
trates in the lung. These inﬁ  ltrates led to acute and 
chronic pneumonia with a consequent epithelial 
cell hyperplasia in the lungs. Lung architecture was 
disrupted with the formation of inflammatory 
pseudopolyps projecting into some of the airway 
lumens.
A feasible mechanism for these ﬁ  ndings is that 
TSP1 activates the latent form of TGFβ1. The lack 
of TSP1 and consequent decrease of TGFβ1 
activation would induce chronic active injury and 
increase of cytokines causing the epithelial 
hyperplasia. The role for TGFβ1 in inﬂ  ammation 
seems to be the prevention of inappropriate 
responses to certain self-or environmental 
antigens.(44) When TGFβ1 signaling is blocked 
in T cells, inﬂ  ammation is most severe at mucosal 
sites where exposure to environmental antigens is 
highest (gut and lung).(45)
TGFβ1 mediates intestinal healing and 
susceptibility to injury in vitro and in vivo.(44) 
Therefore, TGFβ1 activation is a crucial element in 
intestinal homeostasis. Dysregulated responses to 
the normal gut ﬂ  ora have been implicated in the 
pathogenesis of IBD. Mucosal T cells from patients 
with IBD express high levels of Smad7, an inhibitor 
of TGFβ1 signaling, suggesting that dysregulated 
TGFβ1 signaling might have a role in the 
pathogenesis of IBD.(44)
TGFβ1 downregulates epithelial cell prolifera-
tion in vitro and is a potent regulator of immune 
response.(45) By regulating the immune response 
TGFβ1 may reduce the formation of growth factors 
and free radicals, which promote cancer. The tgfb 
deﬁ  cient mice show excessive inﬂ  ammation and 
die in a short time.(46) TSP1 null mice show a 
similar but milder phenotype.
Normal murine and human intestinal mucosa 
express TSP1. In human colons, strong stain has 
been detected in the epithelium with progressive 
decrease in expression in adenomas and carcino-
mas.(47) Diffuse expression has been observed in 
the lamina propria and submucosa and strong 
cytoplasmic and membranous staining in platelets, 
endothelium, ﬁ  broblasts and granulocytes.
Treatment with Dextran Sulfate Sodium (DSS) 
induced a more severe colitis in TSP1
-/-mice.(48) 
Focal inﬂ  ammation was observed in colons after 
only two days of DSS treatment. This ﬁ  nding 
indicates that DSS induces an inflammatory 
response as an early effect, which was intensiﬁ  ed 
by the deﬁ  ciency of TSP1. TSP1
-/- mice displayed 
more bleeding, diarrhea and weight loss than con-
trols as well as more extensive and deeper ulcer-
ations.
A robust angiogenesis was a common feature 
in DSS-induced colitis in both genotypes. This 
process was present on the acute lesions as well as 
in regenerative areas. TSP1
-/- mice showed more 
angiogenesis than controls after only 2 days of DSS 
treatment.
Intense TSP1 expression was detected in the 
submucosa, among the inﬂ  ammatory inﬁ  ltrate in 
WT colons. Fibrin deposits and thrombus were 
also positive for TSP1(48). Upregulation of TSP1 
has been detected in DSS induced-lesions using 
gene microarray technology(49). Gene proﬁ  le also 
showed upregulation of well known factors 
involved in IBD such as tumor necrosis factor 
alpha (TNFα), TGFβ receptors 2 and 3 (TGFβR2 
and TGFβR3) and interleukin 10 (IL-10).
TSP1 is considered a cell adhesion protein. It 
has also been described that bacterial cellular 174
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adherence could be promoted by proteins such 
TSP1.(50) In fact, TSP1 is a ligand protein for 
Clostridium difﬁ  cile at the gastrointestinal epithe-
lium(51) indicating a possible role of TSP1 on 
pathogenic interaction with host cells.
TSP1 might promote bacterial colonization and 
inﬂ  ammation.(50) Studies investigating the impact 
of host TSP1 in the intestinal ﬂ  ora have been car-
ried out.(52) Feces from TSP1
-/- mice contained a 
signiﬁ  cantly lower density of fecal coliforms than 
feces from control mice, exposed or not to DSS. 
Density of lactobacilli did not vary signiﬁ  cantly 
among samples. These data suggest that the lack 
of TSP1 in the colonic epithelium may affect the 
distribution of Escherichia coli (E. coli), possibly 
altering interactions between the bacteria and 
adhesin ligands in the epithelium. The mechanisms 
involved and the possible replacement of com-
mensal E. coli by pathogenic strains during chronic 
colitis warrant further investigation.
TSP1 on Intestinal Carcinogenesis
The functions of TSP1 on cancer are still contro-
versial.(53) They may depend on the lack or pres-
ence of speciﬁ  c receptors or stromal ligands in 
speciﬁ  c tissue types. In some tumors TSP1 seems 
to promote tumor progression.(54–56) Other 
in vivo and clinical studies have shown an inverse 
correlation between TSP1 expression, malignancy 
and poorer prognosis.(57,58) When mice carrying 
the oncogene neu/erbB2 were crossed with TSP1 
null mice, the number of mammary tumors and 






















Figure 1. Schematic overview of main proteins and agents interacting directly or indirectly with TSP1 on angiogenesis, cell cycle and 
inﬂ  ammation. All of them might regulate these mechanisms and consequently the development of colorectal cancer.175
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overexpressing TSP1 showed tumor growth delay 
or inhibition.(59)
Clinical studies have reported a decrease in 
TSP1 protein expression in human colorectal car-
cinomas.(60,61) When TSP1
-/- mice were crossed 
with Apc
Min+/, higher incidence in adenomas and 
carcinomas were observed.(62) Interestingly, no 
differences in vascular density were found between 
these mice and their littermates, suggesting TGFβ1 
activation as the possible mechanism. Mice null 
for TGFβ1 and RAG2 (RAG
-/- mice are born with-
out B and T cells) develop spontaneous adenomas 
and carcinomas in the colon.(63) These tumors 
were more frequently ﬂ  at and highly dysplasic, 
similar to those in Apc
Min+/ TSP1
-/- mice. TSP1 
expression was signiﬁ  cantly decreased in the stro-
mal tissues of Apc
Min+/ polyps. These adenomas 
also displayed signiﬁ  cantly lower PCNA indexes 
for expression of proliferant cell nuclear antigen 
(PCNA) as compared to lesions developed in 
Apc
Min+/ TSP1
-/- mice. These results indicate that 
higher proliferation and accelerated carcinogenesis 
are typical features in the lesions that arose in 
Apc
Min+/ TSP1
-/- mice whose even smaller adeno-
mas showed elevated PCNA indexes. Importantly, 
apoptotic indexes were unmistakably diminished 
on Apc
Min+/ TSP1
-/- tumors, suggesting that TSP1 
might also target tumor cells.
TGFβ1 decreases proliferation in colon carci-
noma cells and a correlation between TSP1 and 
TGFβ1 expression has been found in human colon 
carcinomas.(64,65)
In a retrospective clinical study of more than 60 
colorectal carcinomas, aberrant p53 expression was 
related with high expression of TSP1 and lymph 
node metastases.(66) Patients with primary 
colorectal cancer with low TSP1 expression, with 
or without detection of mp53 gene product, were 
more likely to have lymph node metastasis than 
patients with higher expression.
Using multiple and low doses of DSS, inﬂ  am-
mation, apoptosis and key proteins in intestinal 
carcinogenesis such as p53 and βcatenin were 
evaluated in mice lacking TSP1.(67) In that study, 
endothelial apoptosis was decreased in TSP1
-/- 
colons tissues and secreted fas ligand was dimin-
ished compared to the levels detected in control 
mice. Foci of dysplasia, p53 and βcatenin nuclear 
expression were more frequently seen in TSP1
-/- 
mice. Although the grade of leukocyte inﬁ  ltration 
was similar among the genotypes by the end of the 
study, higher levels of both, vascular endothelial 
growth factor (VEGF) and basic ﬁ  broblast growth 
factor (bFGF) were secreted by TSP1
-/- colons. 
These data support the idea that angiogenesis is 
initiated by chronic inﬂ  ammation but even if this 
condition is resolved, DNA damage and changes 
in the epithelium will perpetuate the angiogenesis 
cycle and trigger carcinogenesis.
Therapeutics Effects of TSP1 
Derived Peptides in Intestinal 
Inﬂ  ammation and Carcinogenesis
In recent studies, anti-angiogenic compounds have 
proved to be effective in IBD models.(68) TSP1 
in combination with irinotecan inhibited tumor 
growth in a model of colon cancer xenograft.(69) 
ABT-510, a peptide derived from TSP1 has been 
studied in clinical studies (phase I and II for lym-
phoma and osteosarcoma). ABT-510 is a truncated 
molecule (recombinant human peptide) having 
most of the carboxyl terminal sequence removed 
with preservation of only a short portion of the 
N-terminal remaining.
ABT-510 has been found effective as therapy 
in brain tumors. In these studies, ABT-510 induced 
apoptosis in tumor cells and diminished angiogen-
esis and proliferation.(70) In the Apc
Min+/model, 
ABT-510 administration using osmotic mini-
pumps signiﬁ  cantly diminished the number of 
adenomas compared with mice controls.(71) 
Angiocidin a peptide with TSP1 binding activity 
has been effective in a human colorectal xenograft 
model. In that study, the anti-tumor activity of this 
molecule is speciﬁ  cally mediated in its TSP1 bind-
ing site.(72,73)
In the DSS model of induced colitis, ABT-510 
consistently diminished angiogenesis and bleeding 
in treated mice.(48) This peptide is an analogue of 
the heptapeptide of TSP1 that interacts with CD36; 
thus, induction of endothelial apoptosis and 
decreased angiogenesis were expected. Surpris-
ingly, mice treated with ABT-510 also displayed 
less colonic inﬂ  ammation. CD36 activation could 
have consequences in the immune response, favor-
ing leukocyte apoptosis and clearance.(74) In 
addition, ABT-510 has been proved to induce cas-
pase activation and apoptosis independently of its 
interaction with CD36.(75)
An important mechanism could be the TSP1/NO 
interaction. Decreasing the levels of NO by TSP1 
will also inhibit leukocyte activation and angiogen-
esis.(33) In addition, diminished endothelial 176
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proliferation and induction of apoptosis by ABT-510 
could restore the quiescent “resting” state of the 
endothelium. An inactive endothelium will seques-
ter fewer leukocytes and will secrete reduced levels 
of pro-angiogenic factors.(11)
In conclusion, the relevance of TSP1 on 
colorectal inﬂ  ammation and carcinogenesis has 
been reviewed emphasizing recent data. TSP1 
seems to play an important pathological function 
in these processes acting by multiple pathways. The 
study of these signaling mechanisms could have a 
signiﬁ  cant impact on future therapeutic strategies 
for IBD and colorectal cancer.
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